{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:07:21Z","timestamp":1790982441675,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.purol.2022.08.006","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T21:56:06Z","timestamp":1668549366000},"page":"1102-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)"],"prefix":"10.1016","volume":"32","author":[{"given":"Y.","family":"Neuzillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Traxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0555","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.purol.2022.08.006_bib0560","article-title":"The global burden of urinary bladder cancer: an update","author":"Richters","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0565","doi-asserted-by":"crossref","first-page":"105346","DOI":"10.1016\/j.envint.2019.105346","article-title":"Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes","volume":"135","author":"Koutros","year":"2020","journal-title":"Environ Int"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0570","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOU.0000000000000753","article-title":"Catalog of exogenous risk factors for bladder carcinogenesis","volume":"30","author":"Jahrreiss","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0575","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ijc.32420","article-title":"The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study","volume":"146","author":"Laaksonen","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0580","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00394-019-01907-8","article-title":"An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies","volume":"59","author":"Witlox","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.purol.2022.08.006_bib0585","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-022-03941-4","article-title":"Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?","author":"Cancrini","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0590","article-title":"A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology","author":"Michel","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0595","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/nau.23457","article-title":"Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review","volume":"37","author":"Ismail","year":"2018","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"10.1016\/j.purol.2022.08.006_bib0600","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1352458506075651","article-title":"GENULF.\u00a0The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines","volume":"13","author":"De S\u00e8ze","year":"2007","journal-title":"Mult Scler"},{"issue":"15","key":"10.1016\/j.purol.2022.08.006_bib0605","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/cncr.32938","article-title":"Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy","volume":"126","author":"Xiang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.purol.2022.08.006_bib0610","doi-asserted-by":"crossref","first-page":"586401","DOI":"10.3389\/fonc.2020.586401","article-title":"Risk and prognosis of secondary bladder cancer after radiation therapy for rectal cancer: a large population-based cohort study","volume":"10","author":"Guan","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.08.006_bib0615","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","article-title":"External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis","volume":"75","author":"Moschini","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0620","series-title":"Label INCa-HAS - Surveillance m\u00e9dico-professionnelle des travailleurs expos\u00e9s ou ayant \u00e9t\u00e9 expos\u00e9s \u00e0 des agents canc\u00e9rog\u00e8nes chimiques: application aux canc\u00e9rog\u00e8nes pour la vessie","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2012"},{"key":"10.1016\/j.purol.2022.08.006_bib0625","series-title":"TNM classification of malignant tumors. UICC International Union Against Cancer","author":"Brierkey","year":"2017"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0630","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2019.10.002","article-title":"Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?","volume":"38","author":"Hentschel","year":"2020","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.08.006_bib0635","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","volume":"4","author":"Van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0640","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0645","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euf.2018.07.012","article-title":"Validation of confocal laser endomicroscopy features of bladder cancer: the next step towards real-time histologic grading","volume":"6","author":"Liem","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0650","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.purol.2022.08.006_bib0655","series-title":"Urinary and male genital tumours","year":"2022"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0660","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskim\u00e4e","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0665","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urolonc.2012.09.011","article-title":"Is the performance of urinary cytology as high as reported historically?. A contemporary analysis in the detection and surveillance of bladder cancer","volume":"32","author":"Yafi","year":"2014","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.08.006_bib0670","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jasc.2021.12.003","article-title":"We'll always have Paris The Paris System for Reporting Urinary Cytology 2022","volume":"11","author":"Wojcik","year":"2022","journal-title":"J Am Soc Cytopathol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0675","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ucl.2015.08.005","article-title":"Current status of urinary biomarkers for detection and surveillance of bladder cancer","volume":"43","author":"Mbeutcha","year":"2016","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0680","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"European Association of Urology\u2013Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0685","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","article-title":"Urinary biomarkers in bladder cancer: a review of the current landscape and future directions","volume":"39","author":"Ng","year":"2021","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0690","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"Bladder Cancer Molecular Taxonomy Group. A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0695","series-title":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Hygi\u00e8ne Hospitali\u00e8re (SFHH), Soci\u00e9t\u00e9 de Pathologie Infectieuse de Langue Fran\u00e7aise (SPILF). R\u00e9vision des recommandations de bonne pratique pour la prise en charge et la pr\u00e9vention des Infections Urinaires Associ\u00e9es aux Soins","author":"Association Fran\u00e7aise d\u2019Urologie (AFU)","year":"2015"},{"issue":"S1","key":"10.1016\/j.purol.2022.08.006_bib0700","article-title":"Recommandations fran\u00e7aises du Comit\u00e9 de Canc\u00e9rologie de l\u2019AFU\u2013Actualisation 2018-2020: tumeurs de la vessie [French ccAFU guidelines\u2013Update 2018-2020: Bladder cancer]","volume":"28","author":"Roupr\u00eat","year":"2019","journal-title":"Prog Urol"},{"issue":"17","key":"10.1016\/j.purol.2022.08.006_bib0705","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.3390\/cancers13174378","article-title":"Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis","volume":"13","author":"Russo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.purol.2022.08.006_bib0710","doi-asserted-by":"crossref","first-page":"644341","DOI":"10.3389\/fonc.2021.644341","article-title":"Novel visualization methods assisted transurethral resection for bladder cancer: an updated survival-based systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0715","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.7150\/jca.34527","article-title":"Diagnostic accuracy of photodynamic diagnosis with 5-aminolevulinic acid, hexaminolevulinate and narrow band imaging for non-muscle invasive bladder cancer","volume":"11","author":"Chen","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.purol.2022.08.006_bib0720","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.euros.2021.06.011","article-title":"Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer","volume":"31","author":"Veeratterapillay","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0725","first-page":"203","article-title":"Urinary tract ultrasonography in the evaluation of haematuria--a report of over 1,000 cases","volume":"84","author":"Datta","year":"2002","journal-title":"Ann R Coll Surg Engl"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0730","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3390\/cancers13061396","article-title":"Imaging and Management of Bladder Cancer","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0735","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.ju.0000169424.79702.6d","article-title":"Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor","volume":"174","author":"Palou","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0740","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00330-019-06529-6","article-title":"Imaging protocols for CT urography: results of a consensus conference from the French Society of Genitourinary Imaging","volume":"30","author":"Renard-Penna","year":"2020","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0745","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00330-019-06530-z","article-title":"Imaging protocols for renal multiparametric MRI and MR urography: results of a consensus conference from the French Society of Genitourinary Imaging","volume":"30","author":"Rouvi\u00e8re","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.purol.2022.08.006_bib0750","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2020.07.021","article-title":"Diagnostic accuracy of multiparametric MRI for local staging of bladder cancer: a systematic review and meta-analysis","volume":"145","author":"Cornelissen","year":"2020","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0755","doi-asserted-by":"crossref","DOI":"10.25011\/cim.v38i4.24262","article-title":"Sensitivity and specificity of diffusion-weighted magnetic resonance imaging in diagnosis of bladder cancers","volume":"38","author":"Zhai","year":"2015","journal-title":"Clin Invest Med"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0760","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2214\/AJR.17.17798","article-title":"DWI as an imaging biomarker for bladder cancer","volume":"208","author":"Yoshida","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0765","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bju.14366","article-title":"Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis","volume":"122","author":"Gandhi","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.08.006_bib0770","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3389\/fonc.2019.00981","article-title":"Diagnostic accuracy of multi-parametric magnetic resonance imaging for tumor staging of bladder cancer: meta-analysis","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0775","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0780","first-page":"10","article-title":"Use of Vesical Imaging-Reporting and Data System (VI-RADS) for detecting the muscle invasion of bladder cancer: a diagnostic meta-analysis","author":"Luo","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.purol.2022.08.006_bib0785","article-title":"Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis","author":"Woo","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0790","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1148\/radiol.2019190648","article-title":"Vying for standardization of bladder cancer MRi interpretation and reporting: VI-RADS","volume":"291","author":"Margolis","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.purol.2022.08.006_bib0795","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.eururo.2020.04.059","article-title":"An International Collaborative consensus statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round Delphi survey, and a consensus meeting","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0800","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/JU.0000000000002444","article-title":"En bloc resection for bladder tumors: an updated systematic review and meta-analysis of its differential effect on safety, recurrence and histopathology","volume":"207","author":"Yanagisawa","year":"2022","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.purol.2022.08.006_bib0805","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/his.14307","article-title":"Feasibility and accuracy of pathological diagnosis in en-bloc transurethral resection specimens versus conventional transurethral resection specimens of bladder tumour: evaluation with pT1 substaging by 10 pathologists","volume":"78","author":"Yanagisawa","year":"2021","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0810","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1089\/end.2021.0688","article-title":"Comparison of clinicopathologic and oncological outcomes between transurethral en bloc resection and conventional transurethral resection of bladder tumor: a systematic review, meta-analysis, and network meta-analysis with focus on different energy sources","volume":"36","author":"Sari Motlagh","year":"2022","journal-title":"J Endourol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0815","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Suarez-Ibarrola","year":"2019","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0820","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.acuro.2017.10.001","volume":"42","author":"Subiela","year":"2018","journal-title":"Actas Urol Esp"},{"issue":"11","key":"10.1016\/j.purol.2022.08.006_bib0825","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1089\/end.2019.0253","article-title":"Long-term prospective outcomes of patients with non-muscle invasive bladder cancer after holmium laser ablation","volume":"33","author":"Darrad","year":"2019","journal-title":"Endourol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0830","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0835","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0840","doi-asserted-by":"crossref","first-page":"23880","DOI":"10.18632\/oncotarget.13054","article-title":"Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0845","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.purol.2022.01.004","volume":"32","author":"Leon","year":"2022","journal-title":"Prog Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0850","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0855","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00345-019-02628-7","article-title":"Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors","volume":"37","author":"Zhou","year":"2019","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0860","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","article-title":"Role of restaging transurethral resection for T1 Non-muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"4","author":"Naselli","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0865","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10147-019-01581-0","article-title":"The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial","volume":"25","author":"Eroglu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.purol.2022.08.006_bib0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0875","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.purol.2022.08.006_bib0880","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/iju.12572","volume":"21","author":"Kohjimoto","year":"2014","journal-title":"I. Int J Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0885","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) Prognostic Factor Risk Goups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0890","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0895","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0900","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0905","author":"Lonati","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0910","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0915","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JU.0000000000002266","article-title":"Role of Lymphadenectomy during radical cystectomy for nonmuscle-invasive bladder cancer: results from a multi-institutional experience","volume":"207","author":"Khanna","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0920","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"BRAVO study group. Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.purol.2022.08.006_bib0925","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.3390\/cancers13102496","article-title":"Differential prognosis and response of Denovo vs. secondary muscle-invasive bladder cancer: an updated systematic review and meta-analysis","volume":"13","author":"Pones","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.purol.2022.08.006_bib0930","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7150\/ijms.49228","article-title":"Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis","volume":"18","author":"Zheng","year":"2021","journal-title":"Int J Med Sci"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0935","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.ju.0000100386.07370.0a","article-title":"A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta\/T1 transitional cell carcinoma of the bladder","volume":"171","author":"Koga","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib0940","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.euf.2018.08.019","article-title":"Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer","volume":"4","author":"Tabayoyong","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0945","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0950","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0955","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0960","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"De Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.purol.2022.08.006_bib0965","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.08.006_bib0970","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.purol.2022.01.001","volume":"32","author":"Audenet","year":"2022","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib0975","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0980","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000477673","article-title":"Safety and Efficacy of Intravesical Bacillus Calmette-Gu\u00e9rin immunotherapy in patients with non-muscle-invasive bladder cancer presenting with asymptomatic bacteriuria: a systematic review","volume":"99","author":"Poletajew","year":"2017","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib0985","article-title":"Gestion pratique de l\u2019ECBU au cours des instillations endov\u00e9sicales de Bacille de Calmette et Gu\u00e9rin (BCG) et de Mitomycine C (MMC)Practical management of ECBU during endovesical instillations of Bacillus Calmette\u2013Gu\u00e9rin (BCG) and Mitomycin C (MMC)","volume":"31","author":"Saint","year":"2021","journal-title":"Prog Urol FMC"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.08.027","article-title":"Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer","volume":"36","author":"Rieken","year":"2018","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib0995","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41585-019-0184-4","article-title":"Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018","volume":"16","author":"Lotan","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib1000","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","article-title":"Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients","volume":"188","author":"Picozzi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.08.006_bib1005","first-page":"100369","article-title":"Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis","volume":"27","author":"Petrelli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23736\/S2724-6051.21.04613-9","article-title":"Active surveillance for recurrent non-muscle invasive bladder cancer: which lessons have we learned during COVID-19 pandemic?","volume":"74","author":"Paciotti","year":"2022","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.purol.2022.08.006_bib1015","doi-asserted-by":"crossref","DOI":"10.1016\/S0302-2838(21)01127-1","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) Experience","author":"Contieri","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.11.005","article-title":"Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer","volume":"34","author":"Hern\u00e1ndez","year":"2016","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.08.006_bib1025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.juro.2017.08.091","article-title":"Active surveillance for low risk nonmuscle invasive bladder cancer: a Confirmatory and resource consumption study from the BIAS Project","volume":"199","author":"Hurle","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib1030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2018.05.006","article-title":"Pathological outcomes for patients who failed to remain under active surveillance for low-risk non-muscle-invasive bladder cancer: update and results from the Bladder Cancer Italian Active Surveillance Project","volume":"1","author":"Hurle","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib1035","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 Study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer-a randomised controlled trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.08.006_bib1040","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib1045","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.eururo.2012.05.032","article-title":"Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study","volume":"62","author":"Colombo","year":"2012","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.purol.2022.08.006_bib1050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/end.2017.0154","article-title":"Holmium YAG photocoagulation: safe and economical alternative to transurethral resection in small nonmuscle-invasive bladder tumors","volume":"31","author":"Planelles G\u00f3mez","year":"2017","journal-title":"J Endourol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib1055","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.acuro.2017.12.002","volume":"42","author":"Rivero Guerra","year":"2018","journal-title":"Actas Urol Esp"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib1060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4111\/icu.20200602","article-title":"Emerging treatments for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib1065","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eururo.2016.02.031","article-title":"Papillary recurrence of bladder cancer at first evaluation after induction bacillus calmette-gu\u00e9rin therapy: implication for clinical trial design","volume":"70","author":"Mmeje","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib1070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.euf.2019.03.012","article-title":"Carcinoma in situ of the urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes","volume":"6","author":"Subiela","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib1075","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.08.006_bib1080","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2013.09.049","article-title":"Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra","volume":"65","author":"Giannarini","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.08.006_bib1085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.purol.2022.08.006_bib1090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.08.006_bib1095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.purol.2022.08.006_bib1100","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722003517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708722003517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:36:10Z","timestamp":1761114970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708722003517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":110,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1166708722003517"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.08.006","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC)","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}